These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27888417)

  • 1. Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.
    Blasco MR; Ramos A; Malo CG; García-Merino A
    J Neurol; 2017 Jan; 264(1):168-169. PubMed ID: 27888417
    [No Abstract]   [Full Text] [Related]  

  • 2. Viral pericarditis following ocrelizumab in a multiple sclerosis patient.
    Miele G; Abbadessa G; Maida E; Bonavita S
    Neurol Sci; 2023 Aug; 44(8):2947-2949. PubMed ID: 37095363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancolitis a novel early complication of Alemtuzumab for MS treatment.
    Vijiaratnam N; Rath L; Xu SS; Skibina O
    Mult Scler Relat Disord; 2016 May; 7():83-4. PubMed ID: 27237765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
    Whiteside D; Barth S; Datta A; Trip SA
    Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Hersh CM; Cohen JA
    Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ITP: tolerance lost.
    Fogarty PF
    Blood; 2011 Dec; 118(24):6232-4. PubMed ID: 22161847
    [No Abstract]   [Full Text] [Related]  

  • 7. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Cuker A; Coles AJ; Sullivan H; Fox E; Goldberg M; Oyuela P; Purvis A; Beardsley DS; Margolin DH
    Blood; 2011 Dec; 118(24):6299-305. PubMed ID: 21960587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.
    Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA
    Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
    Hartung HP; Aktas O; Boyko AN
    Mult Scler; 2015 Jan; 21(1):22-34. PubMed ID: 25344374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current evaluation of alemtuzumab in multiple sclerosis.
    Coyle PK
    Expert Opin Biol Ther; 2014 Jan; 14(1):127-35. PubMed ID: 24289293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Drug For Multiple Sclerosis.
    Aschenbrenner DS
    Am J Nurs; 2017 Jul; 117(7):22. PubMed ID: 28644283
    [No Abstract]   [Full Text] [Related]  

  • 12. Ocrelizumab (Ocrevus) for MS.
    Med Lett Drugs Ther; 2017 Jun; 59(1523):98-101. PubMed ID: 28609424
    [No Abstract]   [Full Text] [Related]  

  • 13. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
    Perumal JS; Foo F; Cook P; Khan O
    Mult Scler; 2012 Aug; 18(8):1197-9. PubMed ID: 22252465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.
    Sheikh-Taha M; Corman LC
    Mult Scler; 2017 May; 23(6):872-874. PubMed ID: 28290754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
    Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
    Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
    [No Abstract]   [Full Text] [Related]  

  • 17. Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis.
    Lau AY; Lui GCY; Chan KP; Au C; Mok VCT; Ziemssen T
    Mult Scler Relat Disord; 2020 Feb; 38():101503. PubMed ID: 31743846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Coles AJ; Cohen JA; Fox EJ; Giovannoni G; Hartung HP; Havrdova E; Schippling S; Selmaj KW; Traboulsee A; Compston DAS; Margolin DH; Thangavelu K; Chirieac MC; Jody D; Xenopoulos P; Hogan RJ; Panzara MA; Arnold DL;
    Neurology; 2017 Sep; 89(11):1117-1126. PubMed ID: 28835403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocarditis following ocrelizumab in relapsing-remitting MS.
    Faissner S; Schwake C; Gotzmann M; Mügge A; Schmidt S; Gold R
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32014890
    [No Abstract]   [Full Text] [Related]  

  • 20. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.
    Brown JW; Coles AJ
    Drug Des Devel Ther; 2013; 7():131-8. PubMed ID: 23494602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.